Dr Giuseppe Curigliano
Giuseppe Curigliano, MD, PhD, is Co-Chair of the Division of Medical Oncology at European Institute of Oncology, in Milan, Italy and is both a clinician and researcher specialising in breast cancer. Dr. Curigliano earned his MD at the Universita’ Cattolica del Sacro Cuore, in Rome, Italy. He also holds a PhD in clinical pharmacology from the University of Pisa. He completed his postdoctoral fellowship in South Carolina Medical School, Charleston (1993-1994) working on clinical immunology and flow cytometry DNA ploidy studies in solid tumors. He moved to the Comprehensive Cancer Center at Columbia University in New York City, NY, USA (1995-96). This working experience was concentrated on molecular epidemiology studies related to carcinogen-DNA adducts, susceptibility genes characterization in solid tumors; gene-environment interactions and development of monoclonal antibodies for carcinogen DNA-adducts detection (4-aminobiphenyl-DNA; 8-deoxyguanosine-DNA; PAH-DNA adducts). He moved to the European Institute of Oncology in 1999. He applied to clinical research his strong basic science background leading several translational research protocols on breast and urogenital cancer. He was committed for 3 years in the phase I unit, contributing to successful development of several targeted agents and cytotoxics. His academic awards include the Toniolo Institute Prize for Medical Research and the AIRC Triennal National Research Grant. He had received several educational and research grants from the Italian Association for Cancer Research (AIRC), the Ital Fund of Clinical research (Ricerca Finalizzata) and the Italian Ministry of Health. Since 2001 he is assistant professor of Clinical Pharmacology at University of Milan. In 2010 he has been a scholar at Dana Farber Cancer Insititute, Boston, USA. He is an active member of the American Society of Clinical Oncology (ASCO) and of the European Society of Medical Oncology (ESMO), Associazione Italiana Oncologia Medica (AIOM). He is founding member of/and scientific coordinator for the International Cardio-Oncology Society (ICOS). He is member of the Scientific Advisory Committee of the International Breast Cancer Study Group. He is member of the Scientific Advisory Committee of the Breast International Group (BIG). He is active member of the Immuno-Task force of the BIG and active member of the BIG-NABCG Immuno Task Force. He has been invited to give lectures in several international meetings, he is a member of the faculty of the European School of Oncology.
Dr. Curigliano’s research experiences include principle or coinvestigator work in several phase I-II clinical trials with targeted agents, cytotoxic and endocrine agents in breast cancer. He have been also involved as principal investigator in several phase I studies with peptide vaccines for breast cancer (either in the adjuvant either in the metastatic setting). Dr Curigliano’s research interests include the biology of breast cancer, predictive markers of response to therapy and new anti-cancer agents. He is the coordinator of a research platform on new drug development in breast cancer at European Institute of Oncology.